Neurology

Linical Celebrates 20 Years of Advancing Clinical Research and Patient WellbeingLinical Celebrates 20 Years of Advancing Clinical Research and Patient Wellbeing

Linical Celebrates 20 Years of Advancing Clinical Research and Patient Wellbeing

OSAKA, Japan, June 10, 2025 /PRNewswire/ -- Linical, a leader in clinical research services, is proud to celebrate its 20th…

12 hours ago
Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society SymposiumOragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium

Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium

SARASOTA, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for…

15 hours ago
Psilera Collaborates with Drug Development Leader Hesperos to Advance Preclinical Modeling of PSIL-006 for Frontotemporal DementiaPsilera Collaborates with Drug Development Leader Hesperos to Advance Preclinical Modeling of PSIL-006 for Frontotemporal Dementia

Psilera Collaborates with Drug Development Leader Hesperos to Advance Preclinical Modeling of PSIL-006 for Frontotemporal Dementia

Strategic agreement underscores Psilera's commitment to advancing PSIL-006 with precision neurology approach Results are expected in Q3 2025 ORLANDO, Fla.…

2 days ago
Rose Hill Life Sciences Executes Exclusive License Agreement with Johns Hopkins University for Restoration of Motor Function Post-Neurological Injury Using PsychedelicsRose Hill Life Sciences Executes Exclusive License Agreement with Johns Hopkins University for Restoration of Motor Function Post-Neurological Injury Using Psychedelics

Rose Hill Life Sciences Executes Exclusive License Agreement with Johns Hopkins University for Restoration of Motor Function Post-Neurological Injury Using Psychedelics

BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Rose Hill Life Sciences, a global leader in the research and intellectual property…

1 week ago
Hyperfine Announces FDA Clearance of a New Next-Generation Swoop® System Powered by Optive AI™ Software, Delivering a Transformative Leap in Image QualityHyperfine Announces FDA Clearance of a New Next-Generation Swoop® System Powered by Optive AI™ Software, Delivering a Transformative Leap in Image Quality

Hyperfine Announces FDA Clearance of a New Next-Generation Swoop® System Powered by Optive AI™ Software, Delivering a Transformative Leap in Image Quality

This major Swoop® system scanner redesign and Optive AI™ software elevate the AI-powered portable MRI experience for clinicians and their…

1 week ago
Hyperfine Announces FDA Clearance of a New Next-Generation Swoop® System Powered by Optive AI™ Software, Delivering a Transformative Leap in Image QualityHyperfine Announces FDA Clearance of a New Next-Generation Swoop® System Powered by Optive AI™ Software, Delivering a Transformative Leap in Image Quality

Hyperfine Announces FDA Clearance of a New Next-Generation Swoop® System Powered by Optive AI™ Software, Delivering a Transformative Leap in Image Quality

This major Swoop® system scanner redesign and Optive AI™ software elevate the AI-powered portable MRI experience for clinicians and their…

1 week ago
Updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommend Use of FES PET Imaging for Lobular Breast CancerUpdated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommend Use of FES PET Imaging for Lobular Breast Cancer

Updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommend Use of FES PET Imaging for Lobular Breast Cancer

NCCN Guidelines® recommend FES PET for systemic staging in certain patients with invasive lobular cancer (ILC), which could facilitate greater…

2 weeks ago
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia GravisCartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology…

2 weeks ago
The Brain Prize: HM The King of Denmark presents prestigious prize to US and German scientists for seminal discoveries in brain cancerThe Brain Prize: HM The King of Denmark presents prestigious prize to US and German scientists for seminal discoveries in brain cancer

The Brain Prize: HM The King of Denmark presents prestigious prize to US and German scientists for seminal discoveries in brain cancer

Two pioneering scientists received The Brain Prize 2025 for their discoveries that open an entirely new way of thinking about…

2 weeks ago